| Drug Name | (AVASTIN (Bevacizumab |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
Safety communication
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Cases of Necrotizing Fasciitis Reported with AVASTIN Reports of severe infectious endophthalmitis following unapproved intravitreal injection use Saudi Food and Drug Authority (SFDA) PRESS RELEASE – Safety of AVASTIN® (bevacizumab) |
| safety communication |
|
| Dear Healthcare provider letter DHPC |
|